scholarly journals Therapies for Neovascular Age-Related Macular Degeneration: Current Approaches and Pharmacologic Agents in Development

2013 ◽  
Vol 2013 ◽  
pp. 1-8 ◽  
Author(s):  
Mostafa Hanout ◽  
Daniel Ferraz ◽  
Mehreen Ansari ◽  
Natasha Maqsood ◽  
Saleema Kherani ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Vascular Diseases ◽  
Age Related Macular Degeneration ◽  
Treatment Modalities ◽  
Vascular Endothelial ◽  
New Therapies ◽  
Age Related ◽  
Early Phase Clinical Trials ◽  
Endothelial Growth Factor ◽  
Pharmacologic Agents

As one of the leading causes of blindness, age-related macular degeneration (AMD) has remained at the epicenter of clinical research in ophthalmology. During the past decade, focus of researchers has ranged from understanding the role of vascular endothelial growth factor (VEGF) in the angiogenic cascades to developing new therapies for retinal vascular diseases. Anti-VEGF agents such as ranibizumab and aflibercept are becoming increasingly well-established therapies and have replaced earlier approaches such as laser photocoagulation or photodynamic therapy. Many other new therapeutic agents, which are in the early phase clinical trials, have shown promising results. The purpose of this paper is to briefly review the available treatment modalities for neovascular AMD and then focus on promising new therapies that are currently in various stages of development.

scholarly journals Treatments for dry age-related macular degeneration: therapeutic avenues, clinical trials and future directions

2021 ◽  
pp. bjophthalmol-2020-318452
Author(s):  
Thales Antonio Cabral de Guimaraes ◽  
Malena Daich Varela ◽  
Michalis Georgiou ◽  
Michel Michaelides
Keyword(s):  
Clinical Trials ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Vascular Endothelial ◽  
Age Related ◽  
Wide Variability ◽  
Dry Amd ◽  
Early Phase Clinical Trials ◽  
Endothelial Growth Factor ◽  
Developed World

Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed world. The identification of the central role of vascular endothelial growth factor (VEGF) in the pathogenesis of neovascular AMD and the introduction of anti-VEGF agents as gold-standard treatment, have drastically changed its prognosis—something yet to be seen in dry AMD. Several therapeutic avenues with a wide variability of targets are currently being investigated in dry AMD. The approaches being investigated to reduce the rate of disease progression include, (1) drugs with antioxidative properties, (2) inhibitors of the complement cascade, (3) neuroprotective agents, (4) visual cycle inhibitors, (5) gene therapy and (6) cell-based therapies. A number of early phase clinical trials have provided promising results, with many more ongoing and anticipated in the near future. In this review, we aim to provide an update of the interventional trials to date and future prospects for the treatment of dry AMD.

Laser Treatment, Photodynamic Therapy, and Radiation Therapy in Wet-Form (Neovascular) Age-Related Macular Degeneration

2017 ◽  
pp. 184-188
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Photodynamic Therapy ◽  
Growth Factor ◽  
Macular Degeneration ◽  
Laser Treatment ◽  
Age Related Macular Degeneration ◽  
Treatment Modalities ◽  
Vascular Endothelial ◽  
Age Related ◽  
Endothelial Growth Factor

Age-related macular degeneration is the leading cause of legal blindness in developed countries. The decrease in central vision, metamorphopsia, and central scotoma affect the reading capacity even in the early stages of the disease. In the historical point of treatment for age-related macular degeneration, laser treatment, radiation treatment, and photodynamic therapy have been used. Today, drugs that inhibit the vascular endothelial growth factor are used widely. In this article, we will discuss the treatment modalities that were used widely before the era of anti-vascular endothelial growth factor drugs.

scholarly journals The role of future treatments in the management of neovascular age-related macular degeneration in Europe

2021 ◽  
pp. 112067212110183
Author(s):  
Laurent Kodjikian ◽  
Carl Joe Mehanna ◽  
Salomon-Yves Cohen ◽  
François Devin ◽  
Sam Razavi ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Phase Iii ◽  
Vascular Endothelial ◽  
Real World Data ◽  
Phase Iii Clinical Trials ◽  
Age Related ◽  
Injection Frequency ◽  
Endothelial Growth Factor

Anti-vascular endothelial growth factor (VEGF) agents have transformed the management of patients with neovascular age-related macular degeneration (nAMD) over the past two decades. However, as more long-term real-world data become available, it is clear that treatment outcomes are inferior to those reported in large, controlled clinical trials. This is largely driven by undertreatment, that is, not maintaining a consistent injection frequency to achieve sustained VEGF suppression, whether due to patient non-compliance, an important injection burden, or non/incomplete anatomical response. Newer therapeutic advances under evaluation hold promise in achieving more, for less. We review the latest drugs currently in or having successfully finished phase III clinical trials, and determine their potential place in the management of patients with nAMD in Europe.

TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS IN EVERYDAY PRACTICE

Retina ◽  
2018 ◽  
Vol 38 (6) ◽  
pp. 1134-1144 ◽  
Author(s):  
Christoph Ehlken ◽  
Thomas Wilke ◽  
Ulrike Bauer-Steinhusen ◽  
Hansjürgen T. Agostini ◽  
Zoran Hasanbasic ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Everyday Practice ◽  
Vascular Endothelial ◽  
Age Related ◽  
Endothelial Growth Factor
Sign in / Sign up

Export Citation Format

Share Document